Literature DB >> 8553311

Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema.

I F Purcell1, P A Corris.   

Abstract

A 28 year old man with asthma, bronchopulmonary aspergillosis, pulmonary thromboembolic disease, and pulmonary hypertension developed Aspergillus fumigatus empyema complicating a pneumothorax. His condition progressively deteriorated despite treatment with intravenous and intrapleural amphotericin B, but improved promptly after substituting nebulised liposomal amphotericin B and oral itraconazole. This experience suggests that nebulised liposomal amphotericin B is well tolerated and merits further assessment in the treatment of pulmonary fungal disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8553311      PMCID: PMC1021361          DOI: 10.1136/thx.50.12.1321

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  7 in total

1.  Treatment of systemic fungal infections with liposomal amphotericin B.

Authors:  G Lopez-Berestein; G P Bodey; V Fainstein; M Keating; L S Frankel; B Zeluff; L Gentry; K Mehta
Journal:  Arch Intern Med       Date:  1989-11

2.  Liposomes for controlled delivery of drugs to the lung.

Authors:  K M Taylor; J M Newton
Journal:  Thorax       Date:  1992-04       Impact factor: 9.139

Review 3.  Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.

Authors:  D W Denning; D A Stevens
Journal:  Rev Infect Dis       Date:  1990 Nov-Dec

4.  Subacute massive pulmonary embolism treated with plasminogen and streptokinase.

Authors:  D A Ellis; E Neville; R J Hall
Journal:  Thorax       Date:  1983-12       Impact factor: 9.139

5.  Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients.

Authors:  O Ringdén; F Meunier; J Tollemar; P Ricci; S Tura; E Kuse; M A Viviani; N C Gorin; J Klastersky; P Fenaux
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

6.  Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients.

Authors:  R Chopra; S Blair; J Strang; P Cervi; K G Patterson; A H Goldstone
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

7.  Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.

Authors:  F Meunier; H G Prentice; O Ringdén
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

  7 in total
  10 in total

1.  Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models.

Authors:  Faisal Usman; Jongdee Nopparat; Ibrahim Javed; Teerapol Srichana
Journal:  Drug Deliv Transl Res       Date:  2020-02       Impact factor: 4.617

2.  Inhaled antimicrobial therapies for respiratory infections.

Authors:  Shin-Woo Kim; Joseph L Kuti; David P Nicolau
Journal:  Curr Infect Dis Rep       Date:  2008-03       Impact factor: 3.725

3.  Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats.

Authors:  E W Van Etten; L E Stearne-Cullen; M ten Kate; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Late pleuropulmonary aspergillosis after the treatment of pneumothorax: report of three cases.

Authors:  S Endo; Y Sohara; F Murayama; T Yamaguchi; T Hasegawa; K Fuse
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 5.  Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.

Authors:  Natalie Z Francis; Kevin W Southern
Journal:  Cochrane Database Syst Rev       Date:  2022-09-02

6.  Pleural aspergillosis with bronchopleurocutaneous fistula and costal bone destruction: a case report.

Authors:  Enrique J Soto-Hurtado; Ester Marín-Gámez; Nuria Segura-Domínguez; Francisco Jiménez-Oñate
Journal:  Lung       Date:  2005 Nov-Dec       Impact factor: 2.584

Review 7.  Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.

Authors:  Neil R H Stone; Tihana Bicanic; Rahuman Salim; William Hope
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

8.  Accumulation of amphotericin B in human macrophages enhances activity against Aspergillus fumigatus conidia: quantification of conidial kill at the single-cell level.

Authors:  B Jahn; A Rampp; C Dick; A Jahn; M Palmer; S Bhakdi
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

Review 9.  Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.

Authors:  Heather E Elphick; Kevin W Southern
Journal:  Cochrane Database Syst Rev       Date:  2016-11-08

Review 10.  Future Directions for Clinical Respiratory Fungal Research.

Authors:  Darius Armstrong-James
Journal:  Mycopathologia       Date:  2021-09-29       Impact factor: 2.574

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.